Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lana E Kandalaft

Showing results (1-10 of 80) with videos related to

Pageof 8
Sort By:
Cancers|November 27, 2021
Vaccines as Priming Tools for T Cell Therapy for Epithelial CancersLana E Kandalaft, Alexandre Harari
Nature Reviews. Drug Discovery|December 2, 2024
Vaccines for cancer prevention: exploring opportunities and navigating challengesMichele Graciotti, Lana E Kandalaft
Current Opinion in Biotechnology|July 15, 2020
Challenges and advantages of cell therapy manufacturing under Good Manufacturing Practices within the hospital settingEmanuela M Iancu, Lana E Kandalaft
Cancers|January 10, 2019
IL-15 and a Two-Step Maturation Process Improve Bone Marrow-Derived Dendritic Cell Cancer VaccineAnanda Mookerjee, Michele Graciotti, Lana E Kandalaft
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 16, 2020
Immune Therapy Opportunities in Ovarian CancerLana E Kandalaft, Kunle Odunsi, George Coukos
Bioimpacts : BI|February 22, 2019
Correction: A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse modelAnanda Mookerjee, Michele Graciotti, Lana E Kandalaft
Cancer Treatment Reviews|November 4, 2018
In vivo cancer vaccination: Which dendritic cells to target and how?Cheryl Lai-Lai Chiang, Lana E Kandalaft
Nature Reviews. Cancer|September 15, 2022
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translationLana E Kandalaft, Denarda Dangaj Laniti, George Coukos
Journal of Translational Medicine|August 7, 2012
A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancerLana E Kandalaft, Daniel J Powell, George Coukos
International Reviews of Immunology|May 12, 2011
Adjuvants for enhancing the immunogenicity of whole tumor cell vaccinesCheryl Lai-Lai Chiang, Lana E Kandalaft, George Coukos
Pageof 8

Showing results (1-10 of 80) with videos related to

Sort By:
Pageof 8
Cancers|November 27, 2021
Vaccines as Priming Tools for T Cell Therapy for Epithelial CancersLana E Kandalaft, Alexandre Harari
Nature Reviews. Drug Discovery|December 2, 2024
Vaccines for cancer prevention: exploring opportunities and navigating challengesMichele Graciotti, Lana E Kandalaft
Current Opinion in Biotechnology|July 15, 2020
Challenges and advantages of cell therapy manufacturing under Good Manufacturing Practices within the hospital settingEmanuela M Iancu, Lana E Kandalaft
Cancers|January 10, 2019
IL-15 and a Two-Step Maturation Process Improve Bone Marrow-Derived Dendritic Cell Cancer VaccineAnanda Mookerjee, Michele Graciotti, Lana E Kandalaft
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 16, 2020
Immune Therapy Opportunities in Ovarian CancerLana E Kandalaft, Kunle Odunsi, George Coukos
Bioimpacts : BI|February 22, 2019
Correction: A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse modelAnanda Mookerjee, Michele Graciotti, Lana E Kandalaft
Cancer Treatment Reviews|November 4, 2018
In vivo cancer vaccination: Which dendritic cells to target and how?Cheryl Lai-Lai Chiang, Lana E Kandalaft
Nature Reviews. Cancer|September 15, 2022
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translationLana E Kandalaft, Denarda Dangaj Laniti, George Coukos
Journal of Translational Medicine|August 7, 2012
A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancerLana E Kandalaft, Daniel J Powell, George Coukos
International Reviews of Immunology|May 12, 2011
Adjuvants for enhancing the immunogenicity of whole tumor cell vaccinesCheryl Lai-Lai Chiang, Lana E Kandalaft, George Coukos
Pageof 8